Quicking Biotech Launches CE-Marked Rapid Point-of-Care Diagnostic Test

New Rapid Diagnostic Receives CE Mark Approval

Quicking Biotech has announced the launch of its latest rapid point-of-care diagnostic test after receiving CE Mark approval, allowing the product to be marketed across countries that recognize the certification. The new diagnostic solution is designed to deliver fast and reliable results, helping healthcare professionals make quicker treatment decisions. The CE Mark confirms that the product meets European safety, quality, and performance requirements for in vitro diagnostic devices. With this approval, Quicking Biotech aims to expand its presence in international healthcare markets while improving access to rapid diagnostic testing. The launch reflects the growing demand for easy-to-use testing solutions that can be used outside traditional laboratory settings. As healthcare systems continue to focus on faster diagnosis and improved patient care, point-of-care testing is becoming an essential part of modern medical practice.

According to Towards Healthcare, the independent diagnostic testing facility market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 41.76 billion in 2026 to approximately USD 82.78 billion by 2035, representing a compound annual growth rate (CAGR) of 7.9% from 2026 to 2035. Rising demand for cost-effective diagnostic services, increasing prevalence of chronic diseases, and expanding access to outpatient healthcare are creating strong market opportunities. Technological advancements, digital diagnostics, and growing investments in modern testing facilities continue to support sustained market expansion.

Designed for Fast and Convenient Testing

The newly launched diagnostic test is built to provide accurate results within a short period, reducing the waiting time associated with conventional laboratory testing. The point-of-care format allows healthcare providers to perform tests directly in clinics, emergency departments, community healthcare centers, and other medical settings without requiring complex laboratory infrastructure. Faster diagnosis enables doctors to begin treatment earlier and improve patient management. The portable nature of the testing solution also makes it suitable for remote healthcare facilities and locations with limited laboratory resources. By simplifying the testing process, Quicking Biotech aims to support healthcare professionals with efficient diagnostic tools that improve workflow while maintaining high testing standards. Rapid and convenient testing is becoming increasingly important as healthcare providers seek to deliver timely medical care and reduce pressure on centralized laboratories.

Supporting Better Healthcare Through Advanced Diagnostics

The introduction of this CE-marked diagnostic test highlights the continued progress being made in point-of-care diagnostic technologies. Healthcare providers are increasingly adopting rapid diagnostic tools because they improve clinical decision-making and reduce delays in patient care. Quicking Biotech's latest product supports this trend by combining reliable performance with user-friendly operation. Rapid diagnostic solutions can improve disease detection, patient monitoring, and treatment planning across a wide range of healthcare settings. The company's expansion also reflects the increasing importance of innovation in diagnostic technology as healthcare systems continue to prioritize faster, more accessible testing. By investing in advanced diagnostic solutions, manufacturers are helping improve healthcare efficiency while supporting better patient outcomes through earlier diagnosis and timely medical intervention.

Growing Global Demand for Point-of-Care Testing

The launch of the new CE-approved diagnostic test comes at a time when demand for point-of-care testing continues to grow worldwide. Healthcare providers are looking for faster diagnostic solutions that reduce laboratory workloads while improving patient access to testing. Advances in diagnostic technologies, digital healthcare, and portable medical devices are driving wider adoption across hospitals, clinics, pharmacies, and community healthcare settings. Companies introducing innovative testing solutions are helping strengthen healthcare systems by making diagnosis faster, simpler, and more accessible. Quicking Biotech's latest product supports this growing trend and demonstrates the industry's focus on delivering reliable diagnostic tools that meet international quality standards. As healthcare continues to evolve, rapid point-of-care diagnostics are expected to play an even greater role in improving disease detection, supporting early treatment, and enhancing overall patient care worldwide.

A recent report by Towards Healthcare highlights that the independent diagnostic testing facility market is witnessing robust growth due to increasing demand for timely diagnostic services, rising adoption of advanced imaging and laboratory technologies, and expanding preventive healthcare programs. Growing collaborations with hospitals, physicians, and insurance providers are improving patient access to specialized testing. Increasing use of artificial intelligence, cloud-based data management, and automated diagnostic systems is expected to enhance operational efficiency while creating long-term growth opportunities across the healthcare industry.